

Resource Summary Report

Generated by [RRID](#) on Aug 23, 2026

tet-pLKO.neo_shGFP

RRID:Addgene_110470

Type: Plasmid

Proper Citation

RRID:Addgene_110470

Plasmid Information

URL: <http://www.addgene.org/110470>

Proper Citation: RRID:Addgene_110470

Insert Name: GFP

Organism: Synthetic

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:31040181](#)

Vector Backbone Description: Backbone Marker:#21916; Backbone Size:10959; Vector Backbone:Tet-pLKO-neo; Vector Types:Mammalian Expression, Lentiviral, RNAi; Bacterial Resistance:Ampicillin

Comments: See Addgene's pLKO family protocol <http://www.addgene.org/plko> on how to use the pLKO family vectors. Plasmid grows more slowly than standard plasmids.

Plasmid Name: tet-pLKO.neo_shGFP

Record Creation Time: 20220422T221537+0000

Record Last Update: 20260815T080140+0000

Ratings and Alerts

No rating or validation information has been found for tet-pLKO.neo_shGFP.

No alerts have been found for tet-pLKO.neo_shGFP.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lin CC, et al. (2024) PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications, 15(1), 2287.

Lin CC, et al. (2023) Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Research square.